Immunome stock holds near the 52-week high

Immunome, Inc. (IMNM) stock traded at USD 27.37 on September 3, 2026, with a market capitalization of USD 3.07 billion and a daily move of 0.13 percent. The stock also sat within a 52-week band of USD 5.15 to USD 30.06, keeping the chart close to the top of that range.

Analyst targets stay above price

Rallies.ai showed 12 analysts covering IMNM with a consensus rating of strong buy and an average price target of USD 36.30 on September 3, 2026. MarketBeat data showed Wedbush analyst David Nierengarten boosted the Immunome target to USD 35.00 on August 12, 2026, from USD 26.05 in the same ranking view.

The comparison is clear: the MarketBeat target of USD 35.00 stood 28.0 percent above the USD 27.37 share price, while the broader consensus target implied 32.4 percent upside.

Revenue remains small

Rallies.ai listed trailing-twelve-month revenue of USD 6.94 million, net income of minus USD 212.39 million and EPS of minus USD 2.43 for Immunome on September 3, 2026. That gap between a USD 3.07 billion valuation and a USD 6.94 million revenue base is why the market still treats the pipeline, not current sales, as the main driver.

Immunome pipeline matters

Immunome is a healthcare sector biotech, and the market response still hinges on development-stage readouts rather than near-term product revenue. The stock's 52-week high of USD 30.06, printed against a low of USD 5.15, shows how sharply sentiment has shifted during 2026.

Price and setup

Immunome stock closed the session at USD 27.37 on September 3, 2026, only USD 2.69 below the 52-week high of USD 30.06. The market cap of USD 3.07 billion and the 0.13 percent daily gain leave the name positioned as a high-beta biotech with a rich valuation relative to current revenue.